2024-03-29T08:25:01Z
https://u-ryukyu.repo.nii.ac.jp/oai
oai:u-ryukyu.repo.nii.ac.jp:02003984
2023-08-03T05:41:41Z
1642838163960:1642838338003
1642838403551:1642838407795
A modified version of galectin-9 induces cell cycle arrest and apoptosis of Burkitt and Hodgkin lymphoma cells
Makishi, Shoko
Okudaira, Takeo
Ishikawa, Chie
Sawada, Shigeki
Watanabe, Toshiki
Hirashima, Mitsuomi
Sunakawa, Hajime
Mori, Naoki
open access
galectin-9
Burkitt lymphoma
Hodgkin lymphoma
NF-κB
AP-1
Identification of galectin-9 as a ligand for T-cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3), expressed on Th1 cells, has established the Tim-3-galectin-9 pathway as a regulator of Th1 immunity. Whereas there is compelling evidence for the effects of galectin-9 on T-cell fate, limited information is available on the impact of galectin-9 on B lymphocytes. We found that protease-resistant galectin-9, hG9NC(null), but not galectin-1 or -8, prevented cell growth of malignant B cells such as Burkitt lymphoma (BL) and Hodgkin lymphoma (HL). β-galactoside binding was essential for galectin-9-induced cell growth suppression. hG9NC(null) induced cell cycle arrest by reducing the expression of cyclin D1, D2, B1, Cdk4, Cdc25C and c-Myc, and apoptosis by reducing the expression of XIAP, c-IAP2 and survivin. Most of these genes are regulated by nuclear factor-κB (NF-κB), and constitutive activation of NF-κB is a common characteristic of both types of malignancies. hG9NC(null) inhibited IκBα phosphorylation, resulting in suppression of NF-κB. AP-1 has also been implicated in the control of cell survival. hG9NC(null) inhibited the expression of JunD, resulting in the suppression of AP-1. Our results suggest that hG9NC(null) is a potentially suitable agent for the management of BL and HL.
論文
Blackwell Publishing
2008-05
eng
journal article
AM
http://hdl.handle.net/20.500.12000/10319
http://hdl.handle.net/20.500.12000/10319
https://u-ryukyu.repo.nii.ac.jp/records/2003984
http://www3.interscience.wiley.com/journal/120120074/abstract
10.1111/j.1365-2141.2008.07229.x
0007-1048
AA00574570
British journal of haematology
142
4
583
594
https://u-ryukyu.repo.nii.ac.jp/record/2003984/files/BJH53.Fig.Final.pdf
https://u-ryukyu.repo.nii.ac.jp/record/2003984/files/BJH53.final.pdf